Journal
CANCERS
Volume 13, Issue 21, Pages -Publisher
MDPI
DOI: 10.3390/cancers13215361
Keywords
liver cancer; microRNA; clinical
Categories
Funding
- Chang Gung Memorial Hospital, Chia-yi, Taiwan [CMRPG6K0031, CMRPG6K0032, CMRPG6K0033]
- Ministry of Science and Technology of the Republic of China - Chang Gung Memorial Hospital, Chia-yi, Taiwan
Ask authors/readers for more resources
Liver cancer, with its high mortality rate globally, lacks early diagnostic tools and effective treatment methods. MicroRNAs play important roles in liver cancer treatment, but there are challenges in improving diagnostic technologies and addressing the side effects of microRNA-based drugs.
Simple Summary: Liver cancer has a high mortality rate. Here, we retrospectively discuss the current progress and dilemmas in the clinical research and treatment of liver cancer. We primarily focus on microRNAs because of their extremely high value in applications and research. We discuss whether microRNAs can be used for the development of better biomarkers and/or therapeutic drugs, and address the difficulties, requirements for improved diagnostic technologies, and side effects related to microRNA-based drugs. Liver cancer is the leading cause of cancer-related mortality in the world. This mainly reflects the lack of early diagnosis tools and effective treatment methods. MicroRNAs (miRNAs) are a class of non-transcribed RNAs, some of which play important regulatory roles in liver cancer. Here, we discuss microRNAs with key impacts on liver cancer, such as miR-122, miR-21, miR-214, and miR-199. These microRNAs participate in various physiological regulatory pathways of liver cancer cells, and their modulation can have non-negligible effects in the treatment of liver cancer. We discuss whether these microRNAs can be used for better clinical diagnosis and/or drug development. With the advent of novel technologies, fast, inexpensive, and non-invasive RNA-based biomarker research has become a new mainstream approach. However, the clinical application of microRNA-based markers has been limited by the high sequence similarity among them and the potential for off-target problems. Therefore, researchers particularly value microRNAs that are specific to or have special functions in liver cancer. These include miR-122, which is specifically expressed in the liver, and miR-34, which is necessary for the replication of the hepatitis C virus in liver cancer. Clinical treatment drugs have been developed based on miR-34 and miR-122 (MRX34 and Miravirsen, respectively), but their side effects have not yet been overcome. Future research is needed to address these weaknesses and establish a feasible microRNA-based treatment strategy for liver cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available